- Home
- EDIT vs EGAN Comparison
EDIT vs EGAN Comparison
Compare EDIT & EGAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- EGAN
- Stock Information
- Founded
- EDIT 2013
- EGAN 1997
- Country
- EDIT United States
- EGAN United States
- Employees
- EDIT N/A
- EGAN N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- EGAN Computer Software: Prepackaged Software
- Sector
- EDIT Health Care
- EGAN Technology
- Exchange
- EDIT Nasdaq
- EGAN Nasdaq
- Market Cap
- EDIT 176.7M
- EGAN 164.0M
- IPO Year
- EDIT 2016
- EGAN 1999
- Fundamental
- Price
- EDIT $1.32
- EGAN $5.74
- Analyst Decision
- EDIT Buy
- EGAN Buy
- Analyst Count
- EDIT 14
- EGAN 2
- Target Price
- EDIT $8.08
- EGAN $9.50
- AVG Volume (30 Days)
- EDIT 3.3M
- EGAN 88.3K
- Earning Date
- EDIT 11-04-2024
- EGAN 02-06-2025
- Dividend Yield
- EDIT N/A
- EGAN N/A
- EPS Growth
- EDIT N/A
- EGAN 37.92
- EPS
- EDIT N/A
- EGAN 0.19
- Revenue
- EDIT $61,759,000.00
- EGAN $90,426,000.00
- Revenue This Year
- EDIT N/A
- EGAN $1.52
- Revenue Next Year
- EDIT N/A
- EGAN $10.05
- P/E Ratio
- EDIT N/A
- EGAN $29.65
- Revenue Growth
- EDIT 150.95
- EGAN N/A
- 52 Week Low
- EDIT $1.28
- EGAN $4.71
- 52 Week High
- EDIT $11.58
- EGAN $8.52
- Technical
- Relative Strength Index (RSI)
- EDIT 24.88
- EGAN 54.15
- Support Level
- EDIT $1.28
- EGAN $5.43
- Resistance Level
- EDIT $2.37
- EGAN $5.87
- Average True Range (ATR)
- EDIT 0.18
- EGAN 0.27
- MACD
- EDIT -0.04
- EGAN 0.00
- Stochastic Oscillator
- EDIT 6.45
- EGAN 52.05
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About EGAN eGain Corporation
eGain Corp automates customer engagement with an innovative Software as a service (SaaS) platform, powered by deep digital, Artificial intelligence (AI), and knowledge capabilities. It operates in the United States, the United Kingdom, and India. The company derives maximum of its revenues from North America. It provides its products to industries such as financial services, telecommunications, retail, government, healthcare, and utilities.